The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include ... to the approval of Abrysvo (manufactured by Pfizer) and Arexvy (manufactured by GlaxoSmithKline ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

For example, after respiratory ... [+] syncytial virus (RSV) cases jumped in December 2024, the New York City Health Department suggested that people mask up in crowded indoor places. (Photo by ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...